Nonacog beta pegol

Drug Profile

Nonacog beta pegol

Alternative Names: 40K PEG-rFIX; Glycopegylated rFIX - Novo Nordisk; La-rFIX derivative - Novo Nordisk; N9 GP; NN 7999; NNC-0156-0000-0009

Latest Information Update: 14 Mar 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Factor IX stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Haemophilia B
  • Phase III Blood coagulation disorders

Most Recent Events

  • 07 Mar 2017 Phase-I clinical trials in Coagulation disorders in Germany (IV) (NCT03075670)
  • 16 May 2016 Preregistration for Haemophilia B (In children, In adults, In adolescents, In the elderly) in USA (IV)
  • 07 Jan 2016 Efficacy, adverse event, and pharmacokinetics data from a phase III trial in Haemophilia B (In adolescents, In the elderly, In adults, In children) released by Novo Nordisk
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top